Bio-Rad Labs (BIO) Tops Q2 EPS by $1.10, Misses on Revenue; Offers Q3 Guidance
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $282.44 --0%
Revenue Growth %: -4.3%
Financial Fact:
Other (income) expense, net: -11.21M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -4.3%
Financial Fact:
Other (income) expense, net: -11.21M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.11, $1.10 better than the analyst estimate of $2.01. Revenue for the quarter came in at $638.5 million versus the consensus estimate of $645.79 million.
GUIDANCE:
Bio-Rad Labs sees Q3 2024 revenue of $638.5-681.1 million, versus the consensus of $661 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Buffalo Potash raises private placement target to C$13.5 million
- Labcorp makes RNA-based colorectal cancer home test available nationwide
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
